HUTCHMED (China) Limited: HUTCHMED Reports 2022 Full Year Results and Provides Business Updates

Landmark licensing deal with Takeda for fruquintinib outside of China, bringing HUTCHMED up to US$1.13 billion, plus royalties, and demonstrating execution of the new global strategy Record Full Year

Related Keywords

China ,Australia ,Japan ,Shanghai ,United States ,Hong Kong ,Hainan ,Macau ,Japanese ,American ,Dennis Riedl ,Zhou Yi ,Atholl Tweedie Freddy Crossley ,Ben Atwell Alex Shaw ,Eli Lilly ,Weiguo Su ,Mark Lee ,Annie Cheng ,American Society Of Clinical Oncology ,Linkedin ,European Lung Cancer Congress ,Epizyme Inc ,Company To Host Annual Results Call Webcast ,Panmure Gordon United Kingdom ,Nasdaq ,China Limited ,Astrazeneca ,European Union Withdrawal ,Takeda Pharmaceuticals International ,Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company ,Shanghai Hutchison Pharmaceuticals ,Public Company Accounting Oversight Board ,Sustainability Working Group ,Stock Exchange Of Hong Kong ,American Neuroendocrine Tumor Society Medical Symposium ,Drug Administration ,Task Force On Financial Disclosures ,Exchange Commission ,National Reimbursement Drug List ,European Medicines Agency ,National Medical Products Administration ,Holding Foreign Companies Accountable ,Sustainability Committee ,Devices Agency ,European Society For Medical Oncology ,Full Year ,Host Annual Results Call ,Webcast Today ,New Drug Applications ,Chief Executive Officer ,Chief Scientific Officer ,Breakthrough Therapy Designation ,Fast Track Designation ,Complete Response Letter ,China Phase ,Hainan Pilot Zone ,Exclusive Worldwide License ,Fruquintinib Outside ,Sustainability Report ,Task Force ,Climate Related Financial Disclosures ,Commission Identified Issuer ,Cash Equivalents ,Short Term Investments ,Consolidated Statements ,Ended December ,Annual Report ,Senior Vice ,Alex Shaw ,Freddy Crossley ,United Kingdom ,Securities Litigation Reform Act ,Holding Foreign Companies Accountable Act ,European Union ,European Society ,New Drug ,National Reimbursement Drug ,National Medical Products ,European Medicines ,Medical Devices ,Marketing Authorization ,World Conference ,European Lung Cancer ,American Society ,Clinical Oncology ,Gastrointestinal Cancers ,Generally Accepted Accounting ,Main Board ,Stock Exchange ,Hutchmed ,Imited ,Reports ,022 ,Bull ,Ear ,Results ,Rovides ,Business ,Updates ,